SCHEMBL15328229

SCHEMBL15328229

O=C(CC(=O)Nc1ccc2c(c1)NC(=O)C2)Nc1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 1/20 0.49
▸ AURKA O14965 1/20 0.47
▸ PDGFRB P09619 1/20 0.47
▸ PDGFRA P16234 1/20 0.47
▸ KDR P35968 1/20 0.47
▸ FLT3 P36888 1/20 0.47
▸ AURKB Q96GD4 1/20 0.47
▸ AURKC Q9UQB9 1/20 0.47
▸ GRIN1 Q05586 1/20 0.47
▸ GRIN2B Q13224 1/20 0.47
▸ KMT2A Q03164 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ TRPV1 Q8NER1 1/20 0.45
▸ HDAC3 O15379 4/20 0.44
▸ HDAC1 Q13547 4/20 0.44
▸ HDAC2 Q92769 4/20 0.44
▸ HDAC6 Q9UBN7 4/20 0.44
▸ HDAC4 P56524 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22425175 0.78 GRIN1 (0.56) KDRGRIN1GRIN2BKMT2ASMN1; SMN2
SCHEMBL15328227 0.78 GRIN1 (0.43) GRIN1GRIN2BKMT2AKDM4ELMNA
SCHEMBL3662896 0.77 CRBN (0.52) SMN1; SMN2CMA1AHRCRBN
SCHEMBL7533313 0.77 AHR (0.50) TRPV1CMA1AHRCRBN
SCHEMBL25567190 0.75 EGFR (0.49) FLT3KMT2ANPC1RAB9AMEN1
SCHEMBL260027 0.75 AHR (0.61) KMT2AKDM4ELMNASMN1; SMN2HDAC3
SCHEMBL30648196 0.75 AHR (0.61) KMT2AKDM4ELMNASMN1; SMN2HDAC3
SCHEMBL1753925 0.74 GAA (0.70) KMT2AKDM4ESMN1; SMN2HDAC3HDAC1
SCHEMBL5843103 0.74 CRBN (0.57) CMA1AHRCRBN
SCHEMBL7717893 0.73 AHR (0.59) KMT2AKDM4ELMNASMN1; SMN2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 — — EP disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 — — US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ING2, CDK2, MAP3K20 CASP3 3845/4885AURKA 176/4885PDGFRB 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback